nonalcoholic fatty liver disease

IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression

1. Berberine (Umbellatine) is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism. 2. Berberine may as a broad-spectrum anti-microbial medicine, a complementary therapeutic agent for HIV/AIDS. 3. Berberine seems to act as an herbal antidepressant and a neuroprotector against neurodegenerative disorders. 4. Berberine is used in histology for staining heparin in mast cells. As a natural dye, berberine has a colour index of 7516. 5. Berberine reduces hepatic fat content in rats with nonalcoholic fatty liver disease; also prevents proliferation of hepatic stellate cells (HSCs), which are central for the development of fibrosis during liver injury. 6. Berberine can ameliorate proinflammatory cytokines-induced intestinal epithelial tight junction damage in vitro, and berberine may be one of the targeted therapeutic agents that can restore barrier function in intestinal disease states. 7. Berberine has antineoplastic effects, including breast cancer, leukemia, melanoma, epidermoid carcinoma, hepatoma, pancreatic cancer, oral carcinoma, tongue carcinoma, glioblastoma, prostate carcinoma and gastric carcinoma, etc.

KHK-IN-5 (Compound 18), a KHK inhibitor, is employed in the study of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2DM).

Hydroxy tipelukast (Compound MN-002), a metabolite of Compound MN-001, is an orally active phenoxyalkyl carboxylic acid. It inhibits hepatic steatosis, lobular inflammation, hepatocellular ballooning, and liver fibrosis, while also reducing hepatic hydroxyproline levels. Hydroxy tipelukast is a promising candidate for the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Neomangiferin (Mangiferin 7-glucoside) has beneficial effects on high fat diet-induced nonalcoholic fatty liver disease in rats. Neomangiferin and mangiferin inhibit tartrate-resistant acid phosphatase, a biochemical marker of osteoclast function and bone resorption.

Pparδ agonist 8 is a potent activator of Pparδ, with potential applications in the study of nonalcoholic fatty liver disease (NAFLD).

GLP-1 receptor agonist 8, a potent agonist of GLP-1 R, holds potential for diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) research[1].

GIP/GLP-1 dual receptor agonist-1 (compound 4), a receptor agonist for both GIP and GLP-1, shows potential for researching metabolic disorders and fatty liver diseases, such as nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) [1].

Cisd2 agonist 2 (compound 6), with an EC50 of 191 nM, is an orally active activator of Cisd2, a protein whose levels are associated with nonalcoholic fatty liver disease (NAFLD). In vivo studies have demonstrated that Cisd2 agonist 2 exhibits no significant toxicity in heterozygous hepatocyte-specific Cisd2 knockout (Cisd2hKO-het) mice [1].

HSD17B13-IN-60 (Compound 126) serves as an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC 50 value of ≤ 0.1 μM against estradiol. This compound has potential applications in the study of liver, metabolic, and cardiovascular diseases, including nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) [1].

HSD17B13-IN-95 (1) serves as an inhibitor for 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value of <0.1 μM for estradiol. It is applicable in researching nonalcoholic fatty liver disease [1].

HSD17B13-IN-96 (3) acts as an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC 50 value of less than 0.1 μM for estradiol. This compound is utilized in researching nonalcoholic fatty liver disease [1].

HSD17B13-IN-98 (5) acts as an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC 50 value of <0.1 μM for estradiol. This compound is applicable in researching nonalcoholic fatty liver disease [1].